This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
AMCP 2020
Presentations
Enfortumab Vedotin | Urothelial Carcinoma | Abstract C32
Real-World Outcomes With Taxane Monotherapy Following Platinum and Anti-Programmed Death 1/Death-Ligand 1 Therapy in Locally Advanced or Metastatic Urothelial Carcinoma
Enfortumab Vedotin | Urothelial Carcinoma | Abstract C33
Quality of Life of Metastatic Urothelial Cancer Patients Treated With Enfortumab Vedotin Following Platinum-containing Chemotherapy and a Checkpoint Inhibitor: Data From EV-201 Cohort 1